Results 191 to 200 of about 8,545 (210)

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses

Virology, 2021
Maikel P Peppelenbosch, Mírzá S Baig, Qiuwei Pan   +2 more
exaly  

Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier

EBioMedicine, 2023
Wen-Ya Peng, Tung-Yi Lin, Jeffrey W Dalley   +2 more
exaly  

Concise Synthesis of Molnupiravir

Synfacts, 2021
openaire   +1 more source

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis

Annals of Medicine, 2022
Zhanhui Feng, Mingwei Wang
exaly  

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Lancet, The, 2023
Joseph F Standing, Saye Khoo, Nigel D Hart   +2 more
exaly  

Molnupiravir: A new candidate for COVID‐19 treatment

Pharmacology Research and Perspectives, 2022
Fariba Pourkarim, Haleh Rezaee
exaly  

Development of a Robust Manufacturing Route for Molnupiravir, an Antiviral for the Treatment of COVID-19

Organic Process Research and Development, 2021
Patrick S Fier, Rachel S Bade, Eric Sirota   +2 more
exaly  

Imbalance in baseline characteristics in molnupiravir trials

BMJ, 2022
openaire   +2 more sources

A Short Synthesis of Molnupiravir

Synfacts, 2020
openaire   +1 more source

Stability Indicating HPTLC Method of Molnupiravir and Comparative Study of Degradant with Marketed Molnupiravir Impurity- A

2022
Tekade, Mayur, Patil, Pallavi
openaire   +1 more source